Selenium Modulates Cancer Cell Response to Pharmacologic Ascorbate. Author Connor Jankowski, Joshua Rabinowitz Publication Year 2022 Type Journal Article Abstract UNLABELLED: High-dose ascorbate (vitamin C) has shown promising anticancer activity. Two redox mechanisms have been proposed: hydrogen peroxide generation by ascorbate itself or glutathione depletion by dehydroascorbate (formed by ascorbate oxidation). Here we show that the metabolic effects and cytotoxicity of high-dose ascorbate in vitro result from hydrogen peroxide independently of dehydroascorbate. These effects were suppressed by selenium through antioxidant selenoenzymes including glutathione peroxidase 1 (GPX1) but not the classic ferroptosis-inhibiting selenoenzyme GPX4. Selenium-mediated protection from ascorbate was powered by NADPH from the pentose phosphate pathway. In vivo, dietary selenium deficiency resulted in significant enhancement of ascorbate activity against glioblastoma xenografts. These data establish selenoproteins as key mediators of cancer redox homeostasis. Cancer sensitivity to free radical-inducing therapies, including ascorbate, may depend on selenium, providing a dietary approach for improving their anticancer efficacy.SIGNIFICANCE: Selenium restriction augments ascorbate efficacy and extends lifespan in a mouse xenograft model of glioblastoma, suggesting that targeting selenium-mediated antioxidant defenses merits clinical evaluation in combination with ascorbate and other pro-oxidant therapies. Keywords Animals, Mice, Humans, NADP, Reactive Oxygen Species, Hydrogen Peroxide, Glutathione, Antioxidants, Ascorbic Acid, Glioblastoma, Glutathione Peroxidase, Selenium, Selenoproteins Journal Cancer Res Volume 82 Issue 19 Pages 3486-3498 Date Published 2022 Oct 04 ISSN Number 1538-7445 DOI 10.1158/0008-5472.CAN-22-0408 Alternate Journal Cancer Res PMCID PMC9532358 PMID 35916672 PubMedPubMed CentralGoogle ScholarBibTeXEndNote X3 XML